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Abstract Green Fluorescent protein (GFP), used as a cellular
tag, provides researchers with a valuable method of measuring
gene expression and cell tracking. However, there is evidence
to suggest that the immunogenicity and cytotoxicity of GFP
potentially confounds the interpretation of in vivo experimen-
tal data. Studies have shown that GFP expression can deteri-
orate over time as GFP tagged cells are prone to death.
Therefore, the cells that were originally marked with GFP
do not survive and cannot be accurately traced over time.
This review will present current evidence for the immunoge-
nicity and cytotoxicity of GFP in in vivo studies by character-
izing these responses.
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Abbreviations
GFP Green fluorescent Protein
eGFP Enhanced green fluorescent protein
CFP Cyan fluorescent protein
YFP Yellow fluorescent protein
RFP Red fluorescent protein
H2-Kd Mouse MHC class I.
IFN gamma Cytokine that is critical for innate and
adaptive immunity against viral, some
bacterial and protozoal infections
MHC Major histocompatibility complex
P53 The tumour suppressor p53 induces cell
death by launching several pathways that
are either dependent on or independent
of gene transcription
ROS Reactive oxygen species
TNF-α Tumor necrosis factor α
NFAT Nuclear factor of activated T-cells
CPP32 Caspace-3
Introduction
Green fluorescent protein (GFP) was discovered in 1961 as a
byproduct of the extraction of aequorin from the Auquorea
victoria jellyfish [1]. The purification, crystallization [2] and
subsequent description of the structural composition of the
GFP chromophore [3] paved the path toward cloning of the
GFP cDNA [4, 5]. The successful expression of GFP led to the
widespread usage of GFP as a gene expression marker and a
molecular and cellular tag.
GFP is composed of 238 amino acids (27 kDa), but only 4
amino acids directly produce fluorescent effects [6]. The fold-
ing and molecular structure (Fig. 1) both play integral roles in
GFP’s fluorescent properties [7]. The formation of the func-
tional chromophore inGFP, and that of analog proteins, entails
three essential steps: protein folding, cyclization of the
tripeptide chromophore motif, and oxidation of the cyclized
chromophore [8–10]. The chromophore is responsible for the
absorption of ultraviolet radiation. Upon excitation, proton
Amir Mehdi Ansari and A. Karim Ahmed contributed equally to this
manuscript
* John W. Harmon
jharmon2@jhmi.edu
1 Department of Surgery and Hendrix Burn/Wound Laboratory,
Baltimore, MD, USA
2 Department of Surgery, The Johns Hopkins University School
of Medicine, Baltimore, MD, USA
Stem Cell Rev and Rep (2016) 12:553–559
DOI 10.1007/s12015-016-9670-8
transfer allows energy to be released in the form of visible
photon emission. Wild-type GFP has a major excitation peak
around 395 nm, a minor excitation around 475 nm, and a
primary emission peak around 509 nm [11–13].
GFP has been engineered to produce an assortment of use-
ful mutants, such as red, cyan, and yellow fluorescent pro-
teins. Additionally, other fluorescent proteins, ranging from
orange to the far-red spectral regions, have been manufactured
[14–17]. When assessing fluorescent proteins for a particular
experimental use, it is crucial to consider many features in-
cluding: photo/temperature-stability as well as color intensity,
cytotoxicity, and immunogenicity [18]. For most purposes,
binding of GFP to a cell surface epitope is the important
mechanism by which GFP labels cells. Fluorescent protein
fusion is another method that targets proteins and tags their
expression. This eliminates the need to label, purify, or deliver
the protein into the cell. This makes it possible to label
and observe a protein’s dynamics, history, steady state
distribution, and association with other proteins in what
were previously inaccessible cell environments [19, 20].
However, fluorescent protein (FP) fusions to native pro-
teins are not small alterations. They constitute significant
additions, which may have steric consequences for protein
function, targeting, and folding.
GFP is widely utilized to label cells for tracking. However,
the cellular damage, caused by GFP transfection/transduction
may lead to misinterpretation of experimental results. The
cellular damage is described as possibly resulting from direct
injury by reactive oxygen species (ROS) generation, initiation
of apoptosis, and damage by immune mechanisms. [10, 13,
21–24]. In this review, we will focus on the mechanisms of
cellular damage caused by GFP-transfection as explored in
various animal models.
Immunogenicity of GFP (Table 1)
Extracellular antigens are taken up and associated with major
histocompatibility complex (MHC) class II molecules in the
endoplasmic reticulum (ER) via invariant chain (li) traf-
ficking. However, MHC class I expression is applied for
intracellular antigens, such as that of a viral infection,
through TAP1/2 transport into the ER. GFP is most com-
monly utilized as a reporter gene insert. As such, it is
processed in the host cell. It is postulated that GFP im-
munogenicity acts through T- cell mediated immunity [8,
11, 25, 26]. The immune response is elicited at the cell’s
surface through class 1 MHC presentation and cytotoxic
T-lymphocyte recognition of the GFP antigen [11]. The murine
MHC class I, known as H-2 K/D/L, consists of extracellular α
heavy chains primarily present on chromosome 17, and anα3-
associated β2-microglobulin on chromosome 2 [27].
Although immunogenicity of GFP and its variants share a
similar mechanism through MHC class 1, animal model and
route of in vivo administration can affect eGFP immunoge-
nicity [6, 11]. To investigate the eGFP elicited cytotoxic im-
mune response researchers utilized Balb/c mice and BM185
(transplantable murine model, pre-B leukemia) cell line.
Typically, intravenously injected wild-type pre-leukemia cells
cause systemic leukemia and mortality of the immunocompe-
tent Balb/c mice; however, when transduced to express eGFP,
the leukemia cells did not cause recipients deaths. In contrast
to the response of the immunocompetent mice, intravenous
administration of wild-type leukemia cells or eGFP-
expressing leukemia cells to Nu/Nu mice, which lack func-
tional T-cells and cytotoxic T lymphocyte (CTL) response,
caused recipient mortality. Subsequent quantification of CTL
response, in immunocompetent mice, demonstrated a three-
fold increase in the CTL response against eGFP-expressing
leukemia cells compared to non eGFP-expressing leukemia
cells. This finding highlights the importance of T-cells in de-
veloping immunologic response against eGFP-expressing leu-
kemia cells [11]. Interestingly, when pre-leukemic cells were
subcutaneously administered to immunocompetent mice, all
of the mice developed rapidly growing subcutaneous tumors
Fig. 1 Molecular Structure of GFP. The tertiary structure of GFP
is a beta barrel structure made up of 11 antiparallel β-strands (1)
and 6 center-positioned alpha helices (2). Interrupting the stranded alpha
helix, there are short helical loops on the ends of the cylindrical structure
(3). A covalently bonded chromophore, 4-(p-hydroxybenzylidene)
imidazolidin-5-one, is located and protected at the center of the
structure (4)
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in normal and eGFP-transduced cells. This suggested that the
route of administration plays an important role in initiating an
immune reaction against eGFP-expressing malignant cells [6].
To confirm and test the aforementioned findings in differ-
ent mice strains, a similar experiment was carried out with
C57BL/6 mice. Subcutaneous injections of EL-4 lymphoma
cells (transplantable murine model, T cell lymphoma) to
C57BL/6 mice caused palpable tumors 13 days after injec-
tions. However, eGFP-expressing EL-4 cells did not cause
tumor growth in any of the recipients [11]. Confirming the
importance of the route of administration in development of
immunologic response against eGFP, transplantable T-cell
lymphoma cells, administered intravenously, did not cause
tumor growth in C57BL/6 mice regardless of whether or not
the lymphoma cells were transduce with eGFP [6].
These findings suggest that eGFP is immunogenic in
Balb/c mice whereas it is only slightly immunogenic in
C57BL/6 mice. Both strain and route of administration play
respective roles in the immune response of eGFP-transduced
cells administered in vivo [6]. Consistent with previous exper-
iments in mice, infusion of autologous eGFP-transduced
CD34+ bone marrow derived hematopoietic stem cells to
rhesus macaques led to lysis of the CD34+ cells and induced
significant CD8+ mediated T-cell reaction [26].
There is also evidence to suggest that there is a rejection of
GFP-expressing cells following transplantation to non-GFP-
expressing wild-type animal, the effect then is diminished
following immunosuppressant therapy. GFP expression in he-
patocytes following transplantation is observably diminished
over time. Hepatocytes obtained from GFP transgenic rats
were transplanted into the livers of wild-type rats. For com-
parison, wild-type hepatocytes were transplanted into GFP-
transgenic rat livers as well [7]. After showing engraftment
using fluorescent microscopy, the transplanted hepatocytes
were tracked for 48 days. Implying an underlying damaging
process, GFP-positive hepatocytes in wild-type rats livers de-
creased more rapidly than the wild-type hepatocytes
transplanted into the GFP transgenic rat livers. Moreover,
GFP-positive hepatocytes attracted CD4+ and CD8+
infiltrating inflammatory cells, which is consistent with an
immunological response [7]. Additionally, immunologic
modification by bone marrow transplantation and administra-
tion of Tacrolimus, a T-cell inhibitor agent, showed increased
survival of transplanted GFP-positive hepatocytes. Host pre-
immunization with GFP-positive hepatocytes led to complete
loss of GFP-positive hepatocytes by day 14 [7].
The results of this study are also congruent with the results
of a GFP gene transfer study into the liver of mice where,
GFP-induced hepatocytes decreased or disappeared in immu-
nocompetent livers 2 weeks after transplantation [28, 29].
To further explore the immunogenicity of the GFP protein,
the effectiveness of the immunosuppressant Cyclosporine was
studied in preventing an immune response to GFP in dogs
transplanted with GFP-transduced CD34+ hematopoietic stem
cells [8] Low GFP expression was associated with more
potent T-cell immune responses to the GFP, when com-
pared to non-transplanted controls. Dogs treated with
cyclosporine after hematopoietic stem cell transplantation
showed stable GFP expression for over 800 days. This sug-
gests that immunosuppression prevents immunoactivation
against transgene products after transplantation of GFP-
transduced hematopoietic stem cells.
Tacrolimus binds to FKBP, and cyclosporine binds to
cyclophilin. Both complexes exert their activity by inhibiting
the calcineurin, a phosphatase that facilitates NFAT transloca-
tion to the nucleus resulting in the upregulation of IL-2. As
such, blocking IL-2 activity results in a loss of T-cell activity,
further elucidating the role of T-cell immunity in the response
against GFP [30, 31].
Other immunological interactions that have been shown to
prolong the in vivo survival of GFP-labeled cells including the
depletion of immune cells [32], use of conventional immuno-
suppressants [33], use of stem/progenitor cells’ as immune
modulators [34] and limiting the amount of antigen, and im-
mune system activation by the antigen-presenting cells [29].
There have been experiments exploring possible ways to
minimize the immunological cytotoxicity in GFP experi-
ments. It has been shown that C57BL/6 have low immunogenic
Table 1 Immunogenicity and
cytotoxicity of GFP GFP Immunogenicity GFP Cytotoxicity
T-cell/MHC I medicated immunogenicity [11] General photocytotoxicity [24]
Variation of T-cell mediated immunogenicity in different
strains [6]
Induction of apoptosis [13]
Variation of T-cell mediated immunogenicity by rout of
administration [6]
Oxidative stress [35, 36]
Immunogenicity in transplanted hepatocytes [7, 28] Cytotoxicity of GFP and its analogs [21]
Diminished immunogenicity by immunosuppressant [8] Cardiac cytotoxicity [38]
Extensive CD8+ T-cell reaction to GFP-induced CD4+
hematopoietic stem cells [26]
Actin-myosin dysfunction in muscle cells [39]
Neurodegeneration [41]
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properties compared to other mice strains such as BALB/c and
mdx [6, 9]. Also, with in vivo studies, using mice myoblast
cells, it has been demonstrated that GFP transgenic mice cells
displayed more effective engraftment capabilities and lasted
longer, compared to GFP-transduced cells, and therefore are
better candidates for dynamic in vivo tracking [9].
Epitope prediction and binding affinity studies revealed
that mouse MHC Class I (H2-Kd) molecules function as a
naturally occurring epitope of eGFP, indicating T-cell activa-
tion cascade [10]. This finding discovered in an experiment
indicating that effector lymphocytes, accountable for eliciting
a response against foreign antigens, did not display a response
to the transplantable sarcoma cells, but did display strong
cytotoxicity against the eGFP-expressing sarcoma cells [10].
It has been demonstrated that transfection and transduction
can be immunogenic in in vivo experiments [35, 36]. This
effect should be differentiated from direct GFP immuno-
genicity. Unfortunately appropriate controls are not included
in many of the papers describing GFP immunogenicity. An
appropriate control would be transfection or transduction with
an empty vector. One paper that includes this appropriate con-
trol is Liu et al. who showed that GFP-transfected cells, com-
pared to the empty-vector transfected cells, have higher levels
of CPP32, an indicator of apoptosis. However, both the groups
demonstrated higher levels of CPP32 compared to non-
transfected cells [13]. In another experiment comparing dif-
ferent analogs of GFP, hepatic cells transfected with GFP,
failed to produce stable progenies compared to the cells
transfected with GFP analogs [21]. This experiment shows
that GFP has special toxicity, independent of the transfec-
tion itself.
Cytotoxicity of GFP (Table 1)
GFP is cytotoxic by a variety of mechanisms in addition to
immunogenicity.
Initiation of the apoptosis cascade has been postulated as a
possible mechanism for the toxicity of GFP and cellular death.
After being transfected by various GFP-plasmid vectors, mouse
embryonic and baby hamster kidney fibroblast cells lost their
GFP signals and disappeared after 120 h [13]. Subsequently,
various morphological (loss of structural integrity) and
molecular changes (redistribution of phosphatidylserine,
an indicator of the apoptosis signaling cascade initiation,
to the cell surface) consistent with GFP-induced apopto-
sis were reported in this experiment. Another valuable
finding suggestive of cellular apoptosis was presence of
CPP32 (Caspace-3, an apoptotic protein) after fading of GFP
signals [13]. CPP32, a member of interleukin-1β converting
enzyme (ICE) family, plays an important role in programed
cell death. It has been shown that the CPP32 is highly
expressed in cells initiating apoptosis. In contrast, inactivation
of CPP32 dramatically reduces apoptosis; therefore, CPP32
activity measurement is a reliable tool for monitoring apopto-
sis [37, 38]. Consistent with morphological changes implying
apoptosis, CPP32 expression level is increased in cells
transfected with GFP-plasmid compared to empty-vector
transfected cells [13].
In addition to initiating the apoptosis cascade, reactive ox-
ygen production induced by GFP has been linked to cellular
toxicity and eventual death in GFP expressing cells. It was
previously described that MHC class I (H2-Kd) is the natural-
ly occurring epitope of eGFP, initiating the activation of CTLs
[10]. However, it remains unclear how the immunogenicity of
GFP through the MHC I pathway is related to the elevated
reactive oxygen species (ROS) observed in various experi-
ments. One proposed mechanism is through the exocytosis
of granzyme B (GrB) through activated CTLs. Activated
CTLs induce the exocytosis of GrB, perforin and GrA through
the death receptor, FAS/FASL. GrB, once exocytosed facili-
tates the release of mitochondrial ROS through the direct
cleavage of caspace-3 and nuclear lamin [39, 40].
Enhanced sensitivity of GFP expressing cells to anticancer
drugs, such as Etoposide, has been associated with increased
levels of ROS in cells. This finding is confirmed by increased
levels of p53-dependent glutathione, which acts as a cellular
defense mechanism in oxidative stress situations [41, 42].
Owing to oxidative stress, neuroblastoma cell lines, which
lack CD80, showed increased sensitivity to cytotoxic agents
when transduced with GFP, eGFP, and YFP [42]. CD80 is a
protein on the activated B-cells and is necessary for co-
stimulation signal required for activation of T-cells. It was
demonstrated that, independent from immunogenicity, both
CD80-negative and CD80-transduced neuroblastoma cells
had significantly enhanced sensitivity to cytotoxic anticancer
agents when transduced with GFP, eGFP, and YFP, [42].
The cellular toxicity of GFP and the cellular toxicity of
GFP analogs are not the same. Cells transfected with GFP
are less stable than those transfected with analogous fluores-
cent proteins, such as CFP, YFP [21]. While investigating rat
liver cells [22, 43], it was found that the GFP-transfected liver
cells yielded 50-fold fewer colonies when compared to the
same cell type transfected with CFP or YFP gene con-
structs. Moreover, colonies that were transfected with
GFP were unable to propagate as stable cell strains, where
colonies transfected with CFP and YFP reached 100 %
cloning efficiency [21].
Normally, an intact cell membrane is impermeable to
propidium iodide, a molecule that can be used to stain cells
by attaching to nucleic acids. Liver cells transfected with GFP
plasmid have been shown to be permeable to propidium
iodide. This could be a result of increased cellular perme-
ability following the initiation of cellular death. The entry
of propidium iodide into the cell leads to exhibition of red
fluorescence after attachment to cellular DNA and RNA,
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which can be distinguished, from GFP signal. Transfection
of rat liver cells with different GFP-plasmids resulted in
similar consequences [21].
In addition to general GFP cellular toxicity, there has been
some evidence that imply organ specific GFP cytotoxicity.
GFP overexpression in the heart caused wild-type mice strains
to develop dilated cardiomyopathy [44]. In this model, GFP
expression was associated with significant increase in heart-
to-body weight ratio, four-chamber dilation and thin myocar-
dium suggestive of dilated cardiomyopathy in young rats.
Observation of more severe cardiomyopathy in cells with
higher GFP expression suggests dose-dependent effects [44].
Impairment of the actin-myosin interaction has also been
reported due to GFP cytotoxicity. eGFP-transduction of
myotubes using a lentivirus vector demonstrated impaired
excitation-contraction coupling and diminished contractile
function of myotubes due to GFP binding to the myosin-
actin binding site [45, 46]. Surprisingly enough, [47], reactive
gliosis and apoptosis of the forebrain area, due to neurodegen-
eration and cellular death, was evidenced in co-expression of
eGFP and β -galactosidase.
In order to detect GFP in living cells, researchers must
utilize light/laser or photoactivation, which uses precise light
wavelengths, to excite the GFP. Photoactivation have been
found to induce phototoxic effects [24, 48–51]. As a conse-
quence, GFP’s cytotoxic effects can be complemented with
the phototoxic effects of wavelength and light intensity during
GFP excitation [52].
Strategies for Utilizing GFP
GFP has been widely utilized as a gene expression marker for
tracking cell progeny in animal models in translational re-
search experiments. However, GFPmay result in variable out-
comes as a cell marker because GFP-expressing cells are lia-
ble to death from immunogenicity, free radical oxygenation,
apoptosis, and other mechanisms. This is particularly impor-
tant to consider when reviewing recent studies where GFP has
been used to label or trace cells in a wide range of experiments
including, but not limited to, dermal component cells [53],
bone marrow derived stem cells/progenitor cells [54], hepato-
cytes [7], cardiomyocytes and neurons [55, 56]. Loss of GFP-
labeled cells results in underestimation of the progeny of the
original cohort.
The appropriate use of GFP is key to gathering reliable data
in animal experiments that require cell tracking. For instance,
a study using eGFP plasmid with a CMV promoter to track the
propagation of prostate cells was deemed insignificant due to
the cytotoxicity of eGFP [57]. One way to assess the cellular
damage caused by eGFP is the utilization of different pro-
moters. For example, eGFP under the control of a CMV pro-
moter and d2eGFP under the control of a damage-inducible
promoter can be used in conjunction to assess cytotoxicity.
The CMV promoter allows eGFP to be continuously
expressed in the cell. The d2eGFP protein contains an amino
acid sequence at its C-terminus, which tags it for degradation,
giving it a shorter half-life. This variant of GFP would
only be expressed if particular transcription factors related
to cell damage were expressed [58]. The cellular expres-
sion level of the d2eGFP could estimate the eGFP-induced
cellular damage [58].
Another possible practical method to minimize GFP toxic-
ity is to choose appropriate animal models. For instance,
where applicable, C57BL/6 should be favored over other
mice strains for cell tracking due to the minimal immuno-
genicity to GFP [11]. In contrast to C57BL/6 mice,
heightened immunogenic response to GFP is seen following
Respiratory Syncytial Virus (RSV) infection in BALB/c mice.
They express significantly higher levels of IFN-γ, MCP-1,
IL-6, and TNF-α. This is due to immunodominant H-2d
CTL in BALB/c mice, resulting in prolonged cytokine
secretion and CTL response [59].
Additionally, cells obtained from GFP transgenic mice
should be preferred over GFP-transduced cells due to their
longevity. It is interesting that GFP immunogenicity and cy-
totoxicity has been demonstrated in multiple animal models.
For example immunogenicity of GFP has been explored in
mouse, rat, dog and monkey models while the possible toxic
effect of GFP is investigated in mice and baby hamster. Many
research experiments are done on large animals such as pigs,
although they share almost a similar immune system with
other animal models, no data is available regarding GFP im-
munogenicity and cytotoxicity in pigs.
Alternatively, GFP can be avoided altogether by using a
different reporter gene based on the type of cell being studied.
For cell lines that are sensitive to oxidative stress and immune
response, GFP analogs should be considered in comparison to
GFP. Analogs such CFP and YFP may be less cytotoxic ex-
pression markers for tracking cells and should be further ex-
plored [10, 13, 21–23].
Conclusion
The problem in the use of GFP for cell tracking is that when a
cohort of cells is labeled with GFP; their failure to track to an
expected destination can be explained by GFP related cell
toxicity rather than by basic biological mechanism. This
means that negative tracing experiments cannot be reliably
interpreted without careful consideration of GFP toxic effects.
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